28222139|t|Leprosy reactions: The predictive value of Mycobacterium leprae - specific serology evaluated in a Brazilian cohort of leprosy patients (U-MDT / CT-BR)
28222139|a|Leprosy reactions, reversal reactions / RR and erythema nodosum leprosum / ENL, can cause irreversible nerve damage, handicaps and deformities. The study of Mycobacterium leprae - specific serologic responses at diagnosis in the cohort of patients enrolled at the Clinical Trial for Uniform Multidrug Therapy Regimen for Leprosy Patients in Brazil / U-MDT / CT-BR is suitable to evaluate its prognostic value for the development of reactions. IgM and IgG antibody responses to PGL-I, LID-1, ND-O-LID were evaluated by ELISA in 452 reaction-free leprosy patients at diagnosis, enrolled and monitored for the development of leprosy reactions during a total person - time of 780,930 person - days, i.e. 2139.5 person - years, with a maximum of 6.66 years follow-up time. Among these patients, 36% (160/452) developed reactions during follow-up: 26% (119/452) RR and 10% (41/452) had ENL. At baseline higher anti-PGL-I, anti-LID-1 and anti-ND-O-LID seropositivity rates were seen in patients who developed ENL and RR compared to reaction-free patients (p<0.0001). Seroreactivity in reactional and reaction-free patients was stratified by bacilloscopic index / BI categories. Among BI negative patients, higher anti-PGL-I levels were seen in RR compared to reaction-free patients (p = 0.014). In patients with 0< BI <3, (36 RR, 36 reaction-free), higher antibody levels to PGL-I (p = 0.014) and to LID-1 (p = 0.035) were seen in RR while difference in anti-ND-O-LID positivity was borderline (p = 0.052). Patients with BI â‰¥3 that developed ENL had higher levels of anti-LID-1 antibodies (p = 0.028) compared to reaction-free patients. Anti-PGL-I serology had a limited predictive value for RR according to receiver operating curve / ROC analyses (area-under-the-curve / AUC = 0.7). Anti LID-1 serology at baseline showed the best performance to predict ENL (AUC 0.85). Overall, detection of anti-PGL-I, anti-LID-1 and anti-ND-O-LID antibodies at diagnosis, showed low sensitivity and specificity for RR prediction, indicating low applicability of serological tests for RR prognosis. On the other hand, anti-LID-1 serology at diagnosis has shown prognostic value for ENL development in BI positive patients. ClinicalTrials.gov NCT00669643.
28222139	0	17	Leprosy reactions	T047	C0343461
28222139	23	39	predictive value	T081	C0032944
28222139	43	63	Mycobacterium leprae	T007	C0026922
28222139	66	74	specific	T080	C0205369
28222139	75	83	serology	T169	C0220911
28222139	84	93	evaluated	T058	C0220825
28222139	99	108	Brazilian	T033	C0238815
28222139	109	115	cohort	T098	C0599755
28222139	119	126	leprosy	T047	C0023343
28222139	127	135	patients	T101	C0030705
28222139	137	142	U-MDT	T061	C0013216
28222139	145	150	CT-BR	T083	C0006137
28222139	152	169	Leprosy reactions	T047	C0343461
28222139	171	189	reversal reactions	T047	C0343461
28222139	192	194	RR	T047	C0343461
28222139	199	224	erythema nodosum leprosum	T047	C0343467
28222139	227	230	ENL	T047	C0343467
28222139	255	267	nerve damage	T037	C0161479
28222139	269	278	handicaps	T033	C0231172
28222139	283	294	deformities	T190	C0302142
28222139	309	329	Mycobacterium leprae	T007	C0026922
28222139	332	340	specific	T080	C0205369
28222139	341	360	serologic responses	T169	C0220911
28222139	364	373	diagnosis	T033	C0011900
28222139	381	387	cohort	T098	C0599755
28222139	391	399	patients	T101	C0030705
28222139	416	430	Clinical Trial	T062	C0008976
28222139	435	442	Uniform	T080	C0205375
28222139	443	460	Multidrug Therapy	T061	C0013216
28222139	473	480	Leprosy	T047	C0023343
28222139	481	489	Patients	T101	C0030705
28222139	493	499	Brazil	T083	C0006137
28222139	502	507	U-MDT	T061	C0013216
28222139	510	515	CT-BR	T083	C0006137
28222139	531	539	evaluate	T058	C0220825
28222139	544	560	prognostic value	T081	C0449821
28222139	569	580	development	T169	C1527148
28222139	584	593	reactions	T169	C0443286
28222139	595	598	IgM	T116,T129	C0020861
28222139	603	606	IgG	T116,T121,T129	C0020852
28222139	607	625	antibody responses	T038	C0003261
28222139	629	634	PGL-I	T109	C0070575
28222139	636	641	LID-1	T129	C0003320
28222139	643	651	ND-O-LID	T129	C0003320
28222139	657	666	evaluated	T058	C0220825
28222139	670	675	ELISA	T059	C0014441
28222139	683	696	reaction-free	T033	C0442740
28222139	697	704	leprosy	T047	C0023343
28222139	705	713	patients	T101	C0030705
28222139	717	726	diagnosis	T033	C0011900
28222139	741	750	monitored	T058	C0030695
28222139	759	770	development	T169	C1527148
28222139	774	791	leprosy reactions	T047	C0343461
28222139	801	806	total	T080	C0439810
28222139	807	813	person	T098	C0027361
28222139	816	820	time	T079	C0040223
28222139	832	838	person	T098	C0027361
28222139	841	845	days	T079	C0439228
28222139	859	865	person	T098	C0027361
28222139	868	873	years	T079	C0439234
28222139	882	889	maximum	T081	C0806909
28222139	898	903	years	T079	C0439234
28222139	904	913	follow-up	T058	C1522577
28222139	914	918	time	T079	C0040223
28222139	932	940	patients	T101	C0030705
28222139	956	965	developed	T169	C1527148
28222139	966	975	reactions	T169	C0443286
28222139	983	992	follow-up	T058	C1522577
28222139	1008	1010	RR	T047	C0343461
28222139	1032	1035	ENL	T047	C0343467
28222139	1040	1048	baseline	T081	C1442488
28222139	1049	1055	higher	T080	C0205250
28222139	1056	1066	anti-PGL-I	T033	C0243095
28222139	1068	1078	anti-LID-1	T033	C0243095
28222139	1083	1096	anti-ND-O-LID	T033	C0243095
28222139	1097	1111	seropositivity	T080	C0521143
28222139	1112	1117	rates	T081	C1521828
28222139	1131	1139	patients	T101	C0030705
28222139	1144	1153	developed	T169	C1527148
28222139	1154	1157	ENL	T047	C0343467
28222139	1162	1164	RR	T047	C0343461
28222139	1165	1173	compared	T052	C1707455
28222139	1177	1190	reaction-free	T033	C0442740
28222139	1191	1199	patients	T101	C0030705
28222139	1212	1226	Seroreactivity	T080	C0205556
28222139	1230	1240	reactional	T169	C0443286
28222139	1245	1258	reaction-free	T033	C0442740
28222139	1259	1267	patients	T101	C0030705
28222139	1272	1282	stratified	T080	C0205363
28222139	1286	1305	bacilloscopic index	T081	C0392762
28222139	1308	1310	BI	T081	C0392762
28222139	1329	1331	BI	T081	C0392762
28222139	1332	1340	negative	T033	C0205160
28222139	1341	1349	patients	T101	C0030705
28222139	1351	1357	higher	T080	C0205250
28222139	1358	1368	anti-PGL-I	T033	C0243095
28222139	1369	1375	levels	T080	C0441889
28222139	1389	1391	RR	T047	C0343461
28222139	1392	1400	compared	T052	C1707455
28222139	1404	1417	reaction-free	T033	C0442740
28222139	1418	1426	patients	T101	C0030705
28222139	1443	1451	patients	T101	C0030705
28222139	1460	1462	BI	T081	C0392762
28222139	1471	1473	RR	T047	C0343461
28222139	1478	1491	reaction-free	T033	C0442740
28222139	1494	1500	higher	T080	C0205250
28222139	1501	1509	antibody	T116,T129	C0003241
28222139	1510	1516	levels	T080	C0441889
28222139	1520	1525	PGL-I	T109	C0070575
28222139	1545	1550	LID-1	T129	C0003320
28222139	1576	1578	RR	T047	C0343461
28222139	1585	1595	difference	T080	C1705242
28222139	1599	1612	anti-ND-O-LID	T033	C0243095
28222139	1613	1623	positivity	T033	C1446409
28222139	1628	1638	borderline	T080	C0205189
28222139	1652	1660	Patients	T101	C0030705
28222139	1666	1668	BI	T081	C0392762
28222139	1677	1686	developed	T169	C1527148
28222139	1687	1690	ENL	T047	C0343467
28222139	1695	1701	higher	T080	C0205250
28222139	1702	1708	levels	T080	C0441889
28222139	1712	1722	anti-LID-1	T033	C0243095
28222139	1723	1733	antibodies	T116,T129	C0003241
28222139	1746	1754	compared	T052	C1707455
28222139	1758	1771	reaction-free	T033	C0442740
28222139	1772	1780	patients	T101	C0030705
28222139	1782	1792	Anti-PGL-I	T033	C0243095
28222139	1793	1801	serology	T059	C0036743
28222139	1816	1832	predictive value	T081	C0032944
28222139	1837	1839	RR	T047	C0343461
28222139	1853	1877	receiver operating curve	T081	C0035787
28222139	1880	1892	ROC analyses	T081	C0035787
28222139	1894	1914	area-under-the-curve	T081	C0376690
28222139	1917	1920	AUC	T081	C0376690
28222139	1929	1939	Anti LID-1	T033	C0243095
28222139	1940	1948	serology	T059	C0036743
28222139	1952	1960	baseline	T081	C1442488
28222139	1977	1988	performance	T052	C1882330
28222139	1992	1999	predict	T078	C0681842
28222139	2000	2003	ENL	T047	C0343467
28222139	2005	2008	AUC	T081	C0376690
28222139	2025	2034	detection	T033	C0442726
28222139	2038	2048	anti-PGL-I	T033	C0243095
28222139	2050	2060	anti-LID-1	T033	C0243095
28222139	2065	2078	anti-ND-O-LID	T033	C0243095
28222139	2079	2089	antibodies	T116,T129	C0003241
28222139	2093	2102	diagnosis	T033	C0011900
28222139	2111	2114	low	T080	C0205251
28222139	2115	2126	sensitivity	T081	C0036667
28222139	2131	2142	specificity	T081	C0037791
28222139	2147	2149	RR	T047	C0343461
28222139	2150	2160	prediction	T078	C0681842
28222139	2173	2176	low	T080	C0205251
28222139	2177	2190	applicability	T080	C1706839
28222139	2194	2211	serological tests	T059	C0036743
28222139	2216	2218	RR	T047	C0343461
28222139	2219	2228	prognosis	T058	C0033325
28222139	2249	2259	anti-LID-1	T033	C0243095
28222139	2260	2268	serology	T059	C0036743
28222139	2272	2281	diagnosis	T033	C0011900
28222139	2292	2308	prognostic value	T081	C0449821
28222139	2313	2316	ENL	T047	C0343467
28222139	2317	2328	development	T169	C1527148
28222139	2332	2334	BI	T081	C0392762
28222139	2335	2343	positive	T033	C1446409
28222139	2344	2352	patients	T101	C0030705
28222139	2354	2372	ClinicalTrials.gov	T170	C4086204